Abstract:Abstract Background There is an increasing incidence of community-acquired Clostridioides difficile infection (CDI), particularly in IBD. Due to a suspected community outbreak in mid-2023, we aimed to investigate the microbiological and antibiotic resistance profile of CDI in an IBD cohort, employing blind central reading, in order to better understand its epidemiology. Methods This was a prospective study of a University Tertiary Hospital in collaboration with the Infection Control Unit and a central laboratory at the forefront of Infectious Diseases investigation in Portugal (Instituto Ricardo Jorge [IRJ]). Faecal samples from all IBD-related CDI from Apr to Oct 2023, were analysed at IRJ, including isolation and identification of C. difficile strains and testing for antimicrobial susceptibility. Infectious diseases investigators were blinded to patients’ data. Results Eleven patients with IBD (median 42 years, 60.0% female) had at least one episode of CDI, comprising 15 IBD-related CDI cases, which represents 26.3% of all CDI cases in this 6-month period. Moreover, this compares to only 14 cases of IBD-related CDI in the previous four years combined. All patients had UC (66.7% extensive), with a median diagnosis of 11 years. All cases were community-acquired, diagnosed in the context of acute worsening of UC symptoms; 40% required hospitalization. Remarkably, only 2 patients had recent antibiotic therapy, while 3 had a recent visit to the emergency department. No predominant ribotype (RT) was recognised: RT 002/2, RT 017, RT 039, RT 078, RT 106 and RT 839 were identified in similar proportions. There were two new RTs detected, which are under characterization. All isolates were susceptible to vancomycin and metronidazole, but 46.7% were resistant to moxifloxacin, which is higher than ever reported in Portugal. Most cases (n=12) were prescribed vancomycin and followed a taper-and-pulse dosing (n=9). None of the three patients who had a recurrence had received taper-and-pulse dosing. Optimization of UC therapy was performed in all cases, including concomitant immunosuppressive therapy escalation when needed, as recommended. Interestingly, one case, despite having tested positive for C. difficile, had a Clostridioides hathewayi isolated in the culture instead. To our knowledge, this is the first case of C. hathewayi associated diarrhoea resolving upon treatment with vancomycin. Conclusion The absence of a predominant ribotype, excluding a community outbreak, demands heightened CDI vigilance in IBD even in absence of traditional risk factors. Alarming moxifloxacin resistance underscores evolving dynamics. A novel C. hathewayi-associated diarrhoea case and the emergence of two new ribotypes adds complexity.

Clostridioides Difficile in Latin America: An Epidemiological Overview

Unveiling the threat: Characterization of Clostridioides difficile Infection in the Northwest Region of Buenos Aires between 2019-2023 and Associated Risk Factors redefined through a Meta-Analysis

Best Practices in the Management of Clostridioides difficile Infection in Developing Nations

Clinical Risk Factors For Clostridium Difficile Infection In A Chinese Tertiary Care Hospital

The burden of Clostridioides difficile infections in South-East Asia and the Western Pacific: A narrative review

Prevalence and Strain Characterization of Clostridioides (Clostridium) difficile in Representative Regions of Germany, Ghana, Tanzania and Indonesia – A Comparative Multi-Center Cross-Sectional Study

Comparative biofilm-forming ability between Clostridioides difficile strains isolated in Latin America and the epidemic NAP1/027 strain

Multicenter study on Clostridioides difficile infections in Mexico: exploring the landscape

Make It Less difficile: Understanding Genetic Evolution and Global Spread of Clostridioides difficile

Molecular Epidemiology of Clostridium Difficile in A Tertiary Hospital of China

Advances in Therapeutic Strategies for the Management of Clostridioides difficile Infection

Clostridioides difficile Infection: Diagnosis and Treatment Challenges

Clostridioides Difficile Infection in the Asia-Pacific Region

Clostridioides difficile and Gut Microbiota: From Colonization to Infection and Treatment

Clostridioides difficile infection: an update

Recent developments in gastrointestinal infections with a focus on cholera

Mechanisms of antibiotic resistance of Clostridioides difficile

Molecular Characterization and Antibiotic Resistance of Clostridioides Difficile in Patients with Inflammatory Bowel Disease from Two Hospitals in China

Fecal Microbiota of Toxigenic Clostridioides difficile-Associated Diarrhea

P1239 Characterization of Clostridioides strains and antibiotic resistance profile in Inflammatory Bowel Disease patients with Clostridioides infection

Clostridioides difficile infection: history, epidemiology, risk factors, prevention, clinical manifestations, treatment, and future options